Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
12 Feb 2021
12 Feb 2021
Historique:
received:
24
07
2020
accepted:
13
01
2021
entrez:
13
2
2021
pubmed:
14
2
2021
medline:
14
2
2021
Statut:
epublish
Résumé
Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2- breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2- early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocyte levels than luminal tumors. Moreover, significant differences in immune infiltrate composition, assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatory antitumor immune infiltrate composition than luminal ones.
Identifiants
pubmed: 33579951
doi: 10.1038/s41523-021-00223-x
pii: 10.1038/s41523-021-00223-x
pmc: PMC7881184
doi:
Types de publication
Journal Article
Langues
eng
Pagination
12Subventions
Organisme : Università degli Studi di Padova (University of Padova)
ID : 60A07-7808/13
Organisme : Istituto Oncologico Veneto (Veneto Institute of Oncology)
ID : L02P38; L04P11
Références
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Front Oncol. 2019 Apr 26;9:303
pubmed: 31106144
Oncol Lett. 2019 Feb;17(2):2177-2186
pubmed: 30675282
NPJ Breast Cancer. 2021 Feb 12;7(1):12
pubmed: 33579951
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
Breast Cancer Res Treat. 2017 Jun;163(2):295-302
pubmed: 28289852
BMC Cancer. 2010 Nov 04;10:604
pubmed: 21050467
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Clin Cancer Res. 2019 Aug 1;25(15):4644-4655
pubmed: 31061067
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
PLoS Med. 2016 Dec 13;13(12):e1002194
pubmed: 27959923
J Clin Oncol. 2014 Apr 1;32(10):1050-7
pubmed: 24590635
J Natl Cancer Inst. 2014 Apr 28;106(5):
pubmed: 24777111
Oncologist. 2019 Nov;24(11):e1055-e1069
pubmed: 31444294
J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8
pubmed: 18812550
Cancer Treat Rev. 2018 Jun;67:63-70
pubmed: 29763779
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
J Natl Cancer Inst. 2016 Oct 13;109(1):
pubmed: 27737921
Cancer Treat Rev. 2016 May;46:9-19
pubmed: 27055087